Recombinant human growth hormone treatment in infants with chronic renal failure

H Maxwell, L Rees

Abstract
Poor growth is a particular problem for children with congenital renal disease. A one year trial of the use of recombinant human growth hormone (rhGH) in eight infants and young children with chronic renal failure is reported here. At entry bone age was less than 2 years, mean (range) chronological age 1-9 (1-3-2-7) years, and glomerular filtration rate (GFR) was 17 (9-42) ml/min/1.73 m². Height standard deviation score (SDS) was -3-3 (-4.6 to -2.0) and height velocity SDS was -1.3 (-3.1 to 0.7). One child was withdrawn when he received a renal transplant after 9-5 months. Two children required dialysis, but remained in the trial. Treatment with rhGH resulted in an increase in height SDS to -2.2 (-4.2 to -0.9), p=0.0002, and height velocity SDS to 1.1 (-0.7 to 2.6), p=0.006. There was no change in GFR and no serious adverse events. There was no effect on plasma lipids, calcium, phosphate, intact parathyroid hormone, or glucose. Alkaline phosphatase rose significantly. Thus rhGH improved growth in eight infants with chronic renal failure, with four children entering the normal range. (Arch Dis Child 1996; 74: 40-43)

Keywords: chronic renal failure, infants, growth, growth hormone.

Poor growth is a particular problem for children with congenital renal disease. Growth in the first two years of life is greater than at any other time; by the age of 2 years children have attained half of their final adult height. Ill health at this time results in a loss of height potential. While subsequent growth in the preschool and early school years is often normal in these children, catch up is rarely seen.

Optimum conservative management, including provision of adequate energy, correction of electrolyte disturbance and acid-base abnormalities, and prevention of renal osteodystrophy goes some way towards improving growth, but many children remain below the normal range. Nasogastric or gastrostomy feeding to ensure adequate nutrition improves growth in some, but not all children.

Growth in the first two years of life is strongly influenced by nutrition. It is now appreciated that the influence of growth hormone is also important at this age; infants who are later diagnosed as having growth hormone deficiency are shorter and lighter than normal.

Recombinant human growth hormone (rhGH) improves growth in older children with chronic renal failure. We present here the results of a one year study of the use of rhGH in infants and young children with chronic renal failure, who were not growing despite good conservative management.

Methods
Criteria for entry to the study were: (1) chronic renal failure with a glomerular filtration rate (GFR) of less than 50 ml/min/1.73 m²; (2) a bone age of less than 2 years; (3) height less than -2 SD or a declining height standard deviation score (SDS) and no improvement in growth despite correction of fluid and electrolyte and acid-base balance, bone disease, and diet (including a trial of tube feeding when necessary); (4) absence of uncontrolled renal bone disease; (5) age less than 1 year at presentation of disease; (6) two previous height measurements in the last 6 months.

Children were excluded if there were other severe congenital abnormalities or if there had been a previous malignancy.

Growth hormone (Genotropin) (Pharmacia, Stockholm) was given as a daily subcutaneous injection (0-14 IU (0-05 mg)/kg/d, equivalent to 1 IU/kg/week) in the evening for one year. Written parental consent was obtained.

PATIENTS
Eight children (three girls, five boys) were enrolled. Mean (range) chronological age was 1-9 (1-3-2-7) years. Six children had congenital structural problems, one had congenital nephropathy, and another had bilateral neonatal renal vein thrombosis. Calculated GFR at the start of treatment was 17 (9-42) ml/min/1.73 m².

Birth weight was 3-19 (2-24-4-50) kg at a mean gestational age of 36-7 (34-41) weeks. Five of the eight infants had a birth weight within the normal range; one child was small for dates and one of the two premature infants had a weight above that expected for gestational age. Growth data for the six months preceding the trial were recorded. At the time of entry to the trial, height SDS was -3-3 (-4.6 to -2.0). Height velocity SDS in the previous six months was -1.3 (-3-1 to 0-7).

MEASUREMENTS
The growth standards of Tanner et al were used to calculate the height and height velocity SDS.
Recombinant human growth hormone in chronic renal failure

Children were seen three monthly, at which time blood was drawn for estimation of urea, creatinine and electrolytes, calcium, phosphate, intact parathyroid hormone (PTH), fasting glucose, insulin, cholesterol, and triglyceride. Height, weight, blood pressure, and adverse events were recorded.

Results

Seven of the eight children completed one year of treatment: one child was withdrawn when he received a renal transplant after 9.5 months of rhGH. Data from this child have been included in the analysis. Two children reached end stage renal failure and were begun on peritoneal dialysis, one after four months the other after 10 months. These children completed the study and their 1 year growth data have been included.

Height SDS increased from $-3.3 \pm 4.6$ to $-2.0$ to $-2.2 \pm 4.2$ to $-0.9$ ($p=0.0002$), fig 1; height velocity SDS increased from $-1.3 \pm 2.7$ to 0.7 to 1.1 $-0.7$ to 2.6 ($p=0.006$), fig 2. Height SDS calculated six months before the study was $-3.2 \pm 0.7 -2.1$, giving a mean increase in height SDS during treatment of $1.1 \pm 0.4$ to 1.7 compared to $0.08 \pm 0.6$ to 0.6 in the preceding six months ($p=0.0016$).

Response to rhGH in this group of patients was unrelated to GFR. The greatest increment in height SDS was seen in the youngest children ($r=-0.794, p=0.019$) (fig 3).

There was no change in blood pressure (table 1). Weight increased from 9.5 (7.5-13.8) kg to 10.6 (8.3-12.9) at six months and 11.7 (8.9-13.8) after one year ($p=0.008$ vs day1). Weight, expressed as per cent of the ideal weight for height, was 98% (79-18) at the start of the study, and 96% (79-127) after one year.

Calculated GFR (ml/min/1.73 m$^2$) in the children remaining on conservative management was unchanged by rhGH treatment, at 17 (9-42) on day 1 and 17 (6-34) after treatment. Results for creatinine, urea, and blood pressure are shown in table 1. There were no significant changes in any of these variables. There were no consistent changes in plasma calcium, phosphate, intact PTH, triglyceride, or cholesterol (table 2). Alkaline phosphatase was raised after six months ($p=0.05$) and remained raised at one year (table 2). Plasma glucose remained constant, but there was a trend for an increase in fasting insulin (table 2). This was not statistically significant, presumably because the sample number was small.

No serious adverse events occurred during the trial.

Discussion

In renal disease poor growth in the first two years of life can result in a significant loss of height potential. Growth thereafter in the preschool and early school years is often normal, so that the children grow parallel to,
but well below the third centile. Catch up growth at this time is rare. At entry to the trial, mean height SDS was −3.3 despite a mean age of just under 2 years. A prospective study of growth in infancy in chronic renal failure reported that the major loss in height and weight SDS occurred within the first six months; this loss can be as great as 0.52 SD per month. Delay in diagnosis can therefore result in a significant loss of growth potential. Optimum conservative management, with correction of electrolytes, acid-base status, and calcium metabolism and provision of adequate nutrition improves growth in some but not all children with chronic renal failure. Improvement is more common in children who present to a paediatric nephrologist below the age of 2 years than those who present at an older age.

Traditionally, it has been thought that growth in infancy is influenced primarily by nutrition, but recent growth hormone has been recognised as a contributing factor at this age. The use of energy supplements in infants with chronic renal failure, by nasogastric or gastrostomy feeding if necessary, does not consistently improve growth. In a placebo controlled trial, rhGH has been shown to improve growth in older prepubertal children with chronic renal failure, and to maintain an improved growth velocity for up to 3 to 5 years, but there is little published data of its use in infants and young children. The results of rhGH treatment in two boys aged less than 2 years with chronic renal failure was reported in abstract form (Linné et al, Pediatr Nephrol 1992; 6: C118). Both showed a good response to treatment. Height SDS did not change in the six months before the trial, while it increased from −3.3 to −2.2 during rhGH treatment. Each child showed an improvement, with four children entering the normal range. The increment in height SDS represents good catch up growth, and interestingly the greatest improvement was seen in the youngest children (fig 3).

The dramatic changes in height velocity in the first two years of life make interpretation of growth data difficult within this age group. Height velocity SDS has been used to allow comparison between height velocities at different ages. Ideally comparison should be with a placebo control group, but ethically this is difficult. With the small number of children involved in this study, it was decided to treat all children. Height SDS was used as the criterion for entry to the trial. Annualisation to compare height velocity at this age can be misleading because of the changing velocity, yet observing growth for one year to obtain an accurate velocity measurement will only lead to a delay in treatment.

Despite the low height SDS before treatment, mean height velocity SDS was within the normal range. This suggests that reduction in height SDS had indeed started early. Furthermore remarkable catch up growth on rhGH was seen despite relatively normal height velocity SDS values during rhGH treatment (most values were within the normal range, albeit in the upper half rather than the lower). Although this is partly an auxiological phenomenon resulting from the high rates of growth seen in infancy, it appears to be easier to achieve catch up growth at this time compared with later childhood, a situation which is also reported following renal transplantation.

The use of energy supplements in infants with chronic renal failure has been recognised as a contributing factor at this age. The use of energy supplements in infants with chronic renal failure, by nasogastric or gastrostomy feeding if necessary, does not consistently improve growth. In a placebo controlled trial, rhGH has been shown to improve growth in older prepubertal children with chronic renal failure, and to maintain an improved growth velocity for up to 3 to 5 years, but there is little published data of its use in infants and young children. The results of rhGH treatment in two boys aged less than 2 years with chronic renal failure was reported in abstract form (Linné et al, Pediatr Nephrol 1992; 6: C118). Both showed a good response to treatment. Height SDS did not change in the six months before the trial, while it increased from −3.3 to −2.2 during rhGH treatment. Each child showed an improvement, with four children entering the normal range. The increment in height SDS represents good catch up growth, and interestingly the greatest improvement was seen in the youngest children (fig 3).

The dramatic changes in height velocity in the first two years of life make interpretation of growth data difficult within this age group. Height velocity SDS has been used to allow comparison between height velocities at different ages. Ideally comparison should be with a placebo control group, but ethically this is difficult. With the small number of children involved in this study, it was decided to treat all children. Height SDS was used as the criterion for entry to the trial. Annualisation to compare height velocity at this age can be misleading because of the changing velocity, yet observing growth for one year to obtain an accurate velocity measurement will only lead to a delay in treatment.

Despite the low height SDS before treatment, mean height velocity SDS was within the normal range. This suggests that reduction in height SDS had indeed started early. Furthermore remarkable catch up growth on rhGH was seen despite relatively normal height velocity SDS values during rhGH treatment (most values were within the normal range, albeit in the upper half rather than the lower). Although this is partly an auxiological phenomenon resulting from the high rates of growth seen in infancy, it appears to be easier to achieve catch up growth at this time compared with later childhood, a situation which is also reported following renal transplantation.

Growth after infancy, in the late preschool and early school years, is often normal in chronic renal failure; it remains to be determined whether or not children treated in infancy with rhGH can maintain their position within the normal range without further rhGH treatment. Perhaps a short course of treatment in infancy can achieve as much benefit as a longer course later in childhood. The benefits have to be weighed against the potential trauma of daily injections in this age group. However these children may need to remain on rhGH to maintain a height within the normal range.

There was no change in calculated GFR in the children who remained on conservative management. Patients with acromegaly have large kidneys that hypertrophy, and rhGH increases GFR and effective renal plasma flow (ERPF) when given to subjects with normal kidneys. We have previously shown that one year of rhGH treatment has no effect on GFR, although there is an increase in ERPF after one week, which is no longer evident at one year.

The long term implications of these findings are unclear. Two of the children were started on dialysis; it is not known whether rhGH treatment was implicated. The group included several children with severely reduced renal function; one child was withdrawn from the study when he received a renal transplant.
It has been much debated whether growth is related to GFR per se. It has been reported by one group that growth declines when the GFR falls below 25 ml/min/1.73 m², and by others that good growth can be achieved in some children even at a very low GFR values. We were unable to find a relation between growth rate and GFR either before or after rhGH treatment, although it is noted that our group of patients is small. The two children who were started on peritoneal dialysis had the smallest increase in height SDS.

No adverse events were reported during the trial. There was no significant change in serum calcium, phosphate, or PTH, but there was an increase in alkaline phosphatase during rhGH treatment, as had been reported previously during accelerated growth in older children on rhGH. Baseline values of cholesterol and triglycerides were variable, with no consistent changes during treatment. There was a trend towards an increase in fasting insulin during rhGH, but no change in fasting glucose. The same findings have been reported previously with the use of rhGH in chronic renal failure; fasting insulin returned to baseline during the second year of treatment.

In summary, one year of rhGH resulted in a marked improvement in height SDS in a group of infants and young children with chronic renal failure. Two children reached end stage disease and required dialysis. GFR in the remaining children was unaffected by rhGH treatment. There were no serious adverse events. Further study is necessary to determine the role and optimum timing of rhGH treatment in renal disease.

This study was supported by Action Research. The growth hormone was kindly provided by Pharmacia. The following paediatric nephrologists contributed to the study: Dr T J Beatte, Glasgow; Dr M Coulthard, Dr P A Smith, Newcastle; Dr F Jewkes, Cardiff; Dr M E McGraw, Bristol; Dr C M Taylor, Birmingham.


